Reprogram the body own
immune system


We are leveraging the natural power of macrophages by engineering them
to attack
some of the most challenging solid tumors.
Our scientists’ pioneering virology medicines is now employed to growing
impact in oncology, delivering innovations once thought impossible in medicine. 

We are making cancer curable for a better and healthier world for all people.

 

 

Reprogram the body own
immune system


We are leveraging the natural power of macrophages by engineering them
to attack
some of the most challenging solid tumors.
Our scientists’ pioneering virology medicines is now employed to growing
impact in oncology, delivering innovations once thought impossible in medicine. 

We are making cancer curable for a better and healthier world for all people.

About Us

Genenta is a clinical-stage biotechnology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors. Intrinsic immunological resistance significantly reduces the effectiveness of most cancer treatments, including leading-edge technologies such as checkpoint inhibitors and CAR-T cell therapies.

Our delivery system takes advantage of a subset of tumor-associated macrophages called TEMs (Tie-2-expressing monocytes) which normally have an affinity for and travel to tumors. Our platform engineers TEMs to deliver an immunotherapeutic payload within tumors, where it can direct the natural immune responses towards malignant cells. Our leading product, Temferon™,  has progressed into Phase 1/2a clinical trials in glioblastoma and is poised to impact other hard-to-treat cancer types.

Cell Theraphy

cell-therapy-for-enduring-protection

We adapted an autologous ex-vivo cell therapy method, using the well-established lentiviral vector, to load the patient’s own TEMs precursors, that are hematopoietic stem and progenitor cells (HSPCs), with an immunotherapeutic transgene sequence.

By subsequently re-introducing these modified cells into the patient, we seek to take advantage of the self-renewing and multi-differentiation nature of HSPCs to enable durable and potentially long-term effects following a one-time treatment.

HSPCs are self-renewing cells capable of differentiating into all types of blood cell. HSPCs can be obtained directly from the bone marrow or from the patient’s peripheral blood with the use of a mobilizing agent. By using  HSPCs, we create a biological reservoir of TEMs loaded with the therapeutic, with the potential to provide enduring surveillance against future relapses or metastases.

News and events

Healthcare Talk by RCS Academy e Corriere della Sera

Speakers: Pierluigi Paracchi, CEO Genenta Science. Register here

21st May, Milan, Corriere della Sera Sala Buzzati (live streaming on corriere.it)

Il ruolo Strategico delle Biotecnologie per la Competitività del Paese.

Speaker: Pierluigi Paracchi, CEO Genenta Science. On. Giulio Centemero, Membro della VI Commissione Finanze See DetailsRegistration here

29th May at 10.30am, Rome, Montecitorio

Il ruolo Strategico delle Biotecnologie per la Competitività del Paese.

Speaker: Pierluigi Paracchi, CEO Genenta Science. On. Giulio Centemero, Membro della VI Commissione Finanze See DetailsRegistration here

29th May at 10.30am, Rome, Montecitorio

Pin It on Pinterest